Zymeworks (ZYME) News Today $15.39 -0.87 (-5.35%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Brokerages Set Zymeworks Inc. (NYSE:ZYME) Target Price at $19.00November 13, 2024 | americanbankingnews.comZymeworks (NYSE:ZYME) Raised to Outperform at Leerink PartnersNovember 11, 2024 | americanbankingnews.comAnalysts Set Expectations for Zymeworks FY2024 EarningsNovember 11, 2024 | americanbankingnews.comFY2024 EPS Estimates for Zymeworks Raised by Leerink PartnrsZymeworks Inc. (NYSE:ZYME - Free Report) - Stock analysts at Leerink Partnrs upped their FY2024 earnings per share estimates for Zymeworks in a research note issued to investors on Thursday, November 7th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings of ($0.3November 11, 2024 | marketbeat.comLeerink Partners Upgrades Zymeworks (ZYME)November 10, 2024 | msn.comZymeworks (NYSE:ZYME) Upgraded by Leerink Partnrs to Strong-Buy RatingNovember 9, 2024 | americanbankingnews.comQ4 Earnings Forecast for Zymeworks Issued By Leerink PartnrsZymeworks Inc. (NYSE:ZYME - Free Report) - Equities research analysts at Leerink Partnrs reduced their Q4 2024 earnings per share (EPS) estimates for Zymeworks in a report issued on Thursday, November 7th. Leerink Partnrs analyst A. Berens now forecasts that the company will earn $0.70 per shareNovember 8, 2024 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Moderate Buy" from AnalystsZymeworks Inc. (NYSE:ZYME - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five analysts that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendNovember 8, 2024 | marketbeat.comZymeworks (NYSE:ZYME) Upgraded at Leerink PartnrsLeerink Partnrs raised shares of Zymeworks from a "hold" rating to a "strong-buy" rating in a research report on Thursday.November 8, 2024 | marketbeat.comCitigroup Issues Positive Forecast for Zymeworks (NYSE:ZYME) Stock PriceNovember 8, 2024 | americanbankingnews.comZymeworks upgraded to Outperform from Market Perform at LeerinkNovember 7, 2024 | markets.businessinsider.comZymeworks (NYSE:ZYME) Upgraded at Leerink PartnersLeerink Partners upgraded shares of Zymeworks from a "market perform" rating to an "outperform" rating and upped their price objective for the stock from $10.00 to $25.00 in a report on Thursday.November 7, 2024 | marketbeat.comZymeworks says first patient dosed in Phase 1 trial of ZW191November 6, 2024 | markets.businessinsider.comZymeworks doses first subject in Phase I trial of ZW191 for solid tumoursNovember 6, 2024 | msn.comZymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-? Expressing Advanced Solid TumorsNovember 5, 2024 | tmcnet.comZymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid TumorsNovember 5, 2024 | globenewswire.comZymeworks price target raised to $18 from $16 at CitiNovember 4, 2024 | markets.businessinsider.comZymeworks (NYSE:ZYME) Hits New 52-Week High on Analyst UpgradeZymeworks (NYSE:ZYME) Reaches New 12-Month High on Analyst UpgradeNovember 4, 2024 | marketbeat.comZymeworks (NYSE:ZYME) Given New $18.00 Price Target at CitigroupCitigroup lifted their price objective on shares of Zymeworks from $16.00 to $18.00 and gave the company a "buy" rating in a research note on Monday.November 4, 2024 | marketbeat.comZymeworks: Turning The Tide With 2 Key Milestones For ZanidatamabNovember 4, 2024 | seekingalpha.comWells Fargo Downgrades Zymeworks (ZYME)November 2, 2024 | msn.comZymeworks Third Quarter 2024 Earnings: Revenues DisappointNovember 2, 2024 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Regeneron (REGN)November 2, 2024 | markets.businessinsider.comZymeworks (NYSE:ZYME) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPSZymeworks (NYSE:ZYME - Get Free Report) released its earnings results on Thursday. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.01. Zymeworks had a negative return on equity of 21.97% and a negative net margin of 179.42%. The firm had revenue of $16.00 million during the quarter, compared to analysts' expectations of $17.90 million. During the same period in the prior year, the company earned ($0.41) earnings per share. The company's quarterly revenue was down 3.1% on a year-over-year basis.November 1, 2024 | marketbeat.comZymeworks (NYSE:ZYME) Shares Gap Down - Should You Sell?Zymeworks (NYSE:ZYME) Shares Gap Down - Here's What HappenedNovember 1, 2024 | marketbeat.comZymeworks (NYSE:ZYME) Earns Neutral Rating from HC WainwrightHC Wainwright reiterated a "neutral" rating and set a $12.00 price objective on shares of Zymeworks in a research report on Friday.November 1, 2024 | marketbeat.comZymeworks (NYSE:ZYME) Rating Lowered to "Equal Weight" at Wells Fargo & CompanyWells Fargo & Company cut Zymeworks from an "overweight" rating to an "equal weight" rating and set a $12.00 price objective for the company. in a report on Friday.November 1, 2024 | marketbeat.comZymeworks Inc (ZYME) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesNovember 1, 2024 | finance.yahoo.comZymeworks Inc. 2024 Q3 - Results - Earnings Call PresentationOctober 31, 2024 | seekingalpha.comAssenagon Asset Management S.A. Purchases Shares of 331,144 Zymeworks Inc. (NYSE:ZYME)Assenagon Asset Management S.A. purchased a new stake in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 331,144 shares of the company's stock, valued at approximately $4,156,000. Assenagon Asset ManagOctober 30, 2024 | marketbeat.comZymeworks to Spotlight Innovations at Investor ConferencesOctober 29, 2024 | msn.comZymeworks price target raised to $28 from $21 at StifelOctober 29, 2024 | markets.businessinsider.comZymeworks Announces Participation in Upcoming Investor ConferencesOctober 29, 2024 | globenewswire.comZymeworks (NYSE:ZYME) Price Target Raised to $28.00 at Stifel NicolausStifel Nicolaus lifted their price objective on Zymeworks from $21.00 to $28.00 and gave the stock a "buy" rating in a report on Monday.October 28, 2024 | marketbeat.comZymeworks Inc.: Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR ConferenceOctober 26, 2024 | finanznachrichten.deZymeworks reports new preclinical data from ADC candidates ZW220 and ZW251October 26, 2024 | markets.businessinsider.comZymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR ConferenceOctober 25, 2024 | globenewswire.comZymeworks (ZYME) Set to Announce Earnings on ThursdayZymeworks (NYSE:ZYME) will be releasing earnings after the market closes on Thursday, October 31, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=634528)October 24, 2024 | marketbeat.comZymeworks’ Early-Stage Progress and Preclinical Innovations Lead to Hold RatingOctober 23, 2024 | markets.businessinsider.comZymeworks Begins Trial for Promising Cancer TherapyOctober 22, 2024 | markets.businessinsider.comZymeworks: First patient dosed in Phase 1 trial of ZW171October 22, 2024 | markets.businessinsider.comZymeworks doses first subject in Phase I trial of ZW171 for various forms of cancerOctober 22, 2024 | finance.yahoo.comHC Wainwright Reiterates Neutral Rating for Zymeworks (NYSE:ZYME)HC Wainwright restated a "neutral" rating and set a $12.00 price objective on shares of Zymeworks in a report on Tuesday.October 22, 2024 | marketbeat.comZymeworks (NYSE:ZYME) Hits New 52-Week High - Should You Buy?Zymeworks (NYSE:ZYME) Hits New 1-Year High - Time to Buy?October 21, 2024 | marketbeat.comZymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing CancersOctober 21, 2024 | globenewswire.comDistant Recurrence Risk in Early Breast Cancer on the DeclineOctober 17, 2024 | msn.comZymeworks (NYSE:ZYME) Hits New 12-Month High - Still a Buy?Zymeworks (NYSE:ZYME) Hits New 1-Year High - What's Next?October 14, 2024 | marketbeat.comAQR Capital Management LLC Cuts Stake in Zymeworks Inc. (NYSE:ZYME)AQR Capital Management LLC decreased its holdings in Zymeworks Inc. (NYSE:ZYME - Free Report) by 80.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 94,272 shares of the company's stock after selling 395,230 shaOctober 13, 2024 | marketbeat.comZymeworks Inc (ZYME) Q2 2024 Earnings Call Highlights: Strategic Shifts and Regulatory MilestonesOctober 10, 2024 | finance.yahoo.comZymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024October 10, 2024 | globenewswire.com Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soon Click here to watch it now. ZYME Media Mentions By Week ZYME Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZYME News Sentiment▼0.420.56▲Average Medical News Sentiment ZYME News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZYME Articles This Week▼74▲ZYME Articles Average Week Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RARE News IMVT News OGN News RYTM News MLTX News APLS News MRUS News IBRX News BHC News AGIO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ZYME) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
